Healthcare
Minerva Surgical, Inc.(UTRS)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 → Jun 15, 2026
- Market Cap
- —
- Revenue Growth
- -3.5%
- EPS Growth
- -58.1%
- Dividend Yield
- 0.0%
Coverage: 248 bars · Jun 20, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Minerva Surgical, Inc. (UTRS) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 20, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -3.5%, EPS growth of -58.1%, a dividend yield of 0.0%. What stands out right now is revenue -3.5%, EPS -58.1%, free cash flow -55.2% with operating margin -61.4% and ROIC -54.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines UTRS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-3.5% vs +7.6% peer median
Operating Margin
Below sector median
-61.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -3.5% and EPS is at -58.1%, with operating margin around -61.4%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UTRS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
UTRS Max Drawdown
-90.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for UTRS and SPY.
Company Overview
Minerva Surgical, Inc.
Other OTC
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
- Leadership
- Darin Hammers
- IPO Date
- Oct 22, 2021
- Employees
- 174
- Street Address
- 4255 Burton Drive
- Mailing
- Santa Clara, CA, 95054
- Region
- Santa Clara, CA, US
- Reporting Currency
- USD
- Investor Line
- 855 646 7874
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 0.0
- Price/Book
- 0.0
Growth
- Revenue
- -3.5%
- EPS
- -58.1%
- Free Cash Flow
- -55.2%
Profitability
- Gross Margin
- 54.2%
- Operating Margin
- -61.4%
- Net Margin
- -67.8%
- ROE
- -111.3%
- ROIC
- -54.3%
Balance Sheet
- Debt/Equity
- 2.31
- Current Ratio
- 2.53
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.